Astellas Pharma Inc. – Product Pipeline Review – H2 2011

Date: November 1, 2011
Pages: 295
Price:
US$ 500.00 US$ 450.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: ACBF11B3373EN
Leaflet:

Download PDF Leaflet

Astellas Pharma Inc. – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Astellas Pharma Inc. - Product Pipeline Review - H2 2011” provides data on the Astellas Pharma Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Astellas Pharma Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Astellas Pharma Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Astellas Pharma Inc. - Brief Astellas Pharma Inc. overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Astellas Pharma Inc. human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Astellas Pharma Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Astellas Pharma Inc.’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Evaluate Astellas Pharma Inc.’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Astellas Pharma Inc. in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Astellas Pharma Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Astellas Pharma Inc..
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Astellas Pharma Inc. and identify potential opportunities in those areas.
Astellas Pharma Inc. Snapshot
Astellas Pharma Inc. Overview
Key Information
Key Facts
Astellas Pharma Inc. – Research and Development Overview
Key Therapeutic Areas
Astellas Pharma Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Astellas Pharma Inc. – Pipeline Products Glance
Astellas Pharma Inc. – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Astellas Pharma Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Astellas Pharma Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Astellas Pharma Inc. – Drug Profiles
Advagraf + Mycophenolate Mofetil
  Product Description
  Mechanism of Action
  R&D Progress
Advagraf + Mycophenolate Mofetil + Basiliximab
  Product Description
  Mechanism of Action
  R&D Progress
AGS-16M8F
  Product Description
  Mechanism of Action
Firmagon
  Product Description
  Mechanism of Action
FK949E
  Product Description
  Mechanism of Action
  R&D Progress
MAXY-4
  Product Description
  Mechanism of Action
MDV3100
  Product Description
  Mechanism of Action
OSI-906 + Tarceva
  Product Description
  Mechanism of Action
  R&D Progress
OSI-930 + Tarceva
  Product Description
  Mechanism of Action
  R&D Progress
YM905
  Product Description
  Mechanism of Action
  R&D Progress
Astellas Pharma Inc. – Pipeline Analysis
Astellas Pharma Inc. – Pipeline Products by Therapeutic Class
Astellas Pharma Inc. - Pipeline Products By Target
Astellas Pharma Inc. – Pipeline Products by Route of Administration
Astellas Pharma Inc. – Pipeline Products by Molecule Type
Astellas Pharma Inc. – Recent Pipeline Updates
Astellas Pharma Inc. - Dormant Projects
Astellas Pharma Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
AGS-8M4
ASK8007
FK778
Astellas Pharma Inc. – Company Statement
Astellas Pharma Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Aug 29, 2011: Astellas Pharma Announces Regulatory Submissions For Mirabegron For Overactive Bladder In US And Europe
Oct 28, 2010: Astellas Pharma Inc. Files Lawsuit Against Nycomed For Patent Infringement In The United States Infringement In The United States
Sep 28, 2011: Astellas Pharma Discontinues Development Of Darexaban
Jul 28, 2011: Astellas Receives Approval For Additional Indication Of Small Bowel Transplant For Prograf And Graceptor In Japan
Mar 21, 2011: Astellas Announces Encouraging Results From Phase III Study of Mirabegron In OAB
Jul 20, 2010: Seattle Genetics And Agensys Initiate Phase I Clinical Trial Of ASG-5ME For Metastatic Pancreatic Cancer
Apr 20, 2011: Astellas Launches Orally Disintegrating Vesicare OD Tablet In Japan
May 19, 2011: Vical To Present TransVax And DNA Vaccines At ASGCT Conference
Feb 18, 2011: Astellas Introduces Advagraf in China-once daily administration, leading the new trend in immunosuppressive therapy after organ transplant
Feb 17, 2011: Astellas Pharma Canada Receives Approval For New Indication Of Topical Eczema Therapy
Sep 15, 2011: Astellas Pharma Announces Administration Of Seasonal Flu Vaccine ASP7374 Completed In Phase I/II Clinical Trial
Feb 15, 2011: Astellas Withdraws Application For Marketing Approval Of YM150 In Japan
Jul 14, 2011: Vical Announces Scientific Advances For TransVax At DNA Vaccines 2011 Conference
Apr 14, 2011: Vical Receives Key European Patent For TransVax Cytomegalovirus Vaccine
Mar 14, 2011: Astellas Submits Application For Marketing Approval Of Bixalomer In Hyperphosphatemia In Japan
Sep 09, 2011: Astellas Pharma To Transfer Distribution Rights For Targocid
Jun 06, 2011: Astellas Announces New Study Results Showing Increased Survival Rate For Metastatic Pancreatic Cancer
Mar 06, 2003: Cell Pathways Completes Enrollment in Phase III Trial Of Aptosyn And Taxotere In Second-Line Non-Small Cell Lung Cancer.
Mar 06, 2002: Protopic is Approved for the Treatment of Atopic Dermatitis In The European Union
Oct 05, 2001: Fujisawa Launches Protopic in Canada
Sep 05, 2011: Results From Osaka Study Presented At European Society For Organ Transplantation 2011 Congress
Mar 02, 2011: Vical Receives Positive Scientific Advice From EMA For TransVax Phase III Trial
Oct 01, 2002: OSI Pharmaceuticals Announces Initiation Of Two Phase II Clinical Trials For OSI-211
Sep 01, 2010: Agensys Initiates Phase I Clinical Trial Of AGS-16M8F For Renal Cancer
Sep 01, 2005: A multi-center study of short and long-term use of Protopic Ointment in atopic dermatitis patients.
Jul 01, 2011: Astellas Receives Approval For Betanis Tablet In Japan For Overactive Bladder
Jun 01, 2009: Astellas receives approval from FDA for use of Prograf in conjunction with MMF in kidney transplant recipients
Jun 01, 2006: Astellas Launches "Vesicare" for the treatment of Overactive Bladder in Japan
Apr 01, 2005: Black box warning was added for Elidel, Protopic by FDA: the manufacturers have agreed to conduct research to determine if there is a risk of cancer in humans.
Mar 01, 2006: FDA approved updated black box warning label for Elidel and Protopic.
Financial Deals Landscape
Astellas Pharma Inc., Deals Summary
Astellas Pharma Inc., Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
MediGene Completes Sale Of European Rights For Eligard To Astellas
Astellas Pharma To Acquire Assets And Rights Of Diannexin From Pharmaceutical Product
Prosidion Acquires Pharmaceutical Assets From 7TM Pharma
Astellas Pharma Acquires AMEVIVE Rights And Assets From Biogen Idec
Astellas Pharma Acquires Research Facility From Dynogen Dynogen Pharmaceuticals
Prosidion Acquires Dipeptidyl Peptidase-IV Platform From Probiodrug
Venture Financing
Prolysis Secures $10 Million In Venture Financing
Partnerships
Teijin Pharma Enters Into Distribution Agreement With Astellas Pharma For Febuxostat
Pfizer Amends Its Co-Promotion Agreement With Astellas Pharma
Astellas Pharma Enters Into Distribution Agreement With Abbott Japan For Luvox
BioFocus Enters Into Co-Development Agreement With Astellas Pharma
Multiple Myeloma Research Foundation Enters Into Co-Development Agreement With Astellas Pharma
Cell Signaling Technology Enters Into Co-Marketing Agreement With Astellas Pharma
Maruho Enters Into Co-Marketing Agreement With Astellas
Astellas Pharma Enters Into Drug Discovery Collaboration With NITE
Astellas Pharma Enters Into An Agreement With Sanofi-Aventis
Dong-A Pharmaceutical Enters Into Co-Promotion Agreement With Astellas Pharma Korea
Astellas Pharma Enters Into Co-Development Agreement With UMN Pharma
Astellas Pharma Enters Into Co-Marketing Agreement With Bayer Schering Pharma
OM PHARMA Enters Into Co-Marketing Agreement With Astellas Pharma
Ambit Biosciences Enters Into Co-Development Agreement With Astellas Pharma
Medivation Enters Into Co-Development Agreement With Astellas Pharma
Maxygen Forms Joint Venture With Astellas Pharma
Pfizer Enter Into Co-Promotion Agreement With Astellas Pharma
Astellas Pharma Enters Into Co-Promotion Agreement With AstraZeneca
Astellas Pharma Enters Into Co-Marketing Agreement With Zogenix
REGiMMUNE Enters Into Co-Development Agreement With Astellas Pharma
Astellas Pharma Enters Into Agreement With Maxygen
Astellas Pharma Enters Into Licensing Agreement With Regeneron Pharmaceuticals
Astellas Enters Into License Agreement With Kirin Brewery Company
Eli Lilly Enters Into Licensing Agreement With OSI Pharmaceuticals
Prosidion Enters Into License Agreement With Bristol-Myers Squibb
Ingenuity Systems Enters Into Licensing Agreement With Astellas Pharma
Theravance Extends Licensing Agreement With Astellas
CV Therapeutics Amends Licensing Agreement With Astellas US
Astellas Pharma Enters Into Licensing Agreement With FibroGen
Sanofi-Aventis Enters Into Licensing Agreement With Astellas Pharma
Astellas Pharma Enters Into Licensing Agreement With Toyama Chemical
Astellas Pharma Enters Into Licensing Agreement With Immuno-Bioogical Laboratories
Ferring Pharmaceuticals Enters Into Licensing Agreement With Astellas Pharma
Astellas Pharma Enters Into Licensing Agreement With XenoPort
Astellas Pharma Enters Into Licensing Agreement With Theravance
OSI Pharmaceuticals Enters Into License Agreement With Japanese Pharmaceutical Company
Fujisawa Pharmaceutical Enters Into Licensing Agreement With Carlsson Research
Equity Offering
Cytori Therapeutics Announces Private Placement Of $10 Million
Cardiome Pharma Completes Private Placement Of $4 Million
Asset Transactions
Prosidion Completes Sale Of Dipeptidyl Peptidase IV Patent Estate And Associated Royalty Interest To Royalty Pharma
APP Pharmaceuticals Acquires Manufacturing Plant From Astellas Phama
Temmler Pharma Acquires Three European Plants From Astellas Pharma
QLT Acquires Full Rights To Aczone From Astellas
Acquisition
Astellas Pharma Acquires Remaining 83% Interest In Perseid Therapeutics From Maxygen
Astellas Pharma Acquires OSI Pharmaceuticals
Astellas Acquires Agensys
Astellas Pharma Sells Hoshienu Pharma To Choseido Pharmaceutical
Daiichi Sankyo Acquires Zepharma From Astellas Pharma
OSI Pharmaceuticals Acquires Remaining Stake In Prosidion
Prosidion Acquires AdipoGenix
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Astellas Pharma Inc. – Pipeline by Therapy Area and Indication, H2 2011
Astellas Pharma Inc. – Pipeline by Stage of Development, H2 2011
Astellas Pharma Inc. – Monotherapy Products in Pipeline, H2 2011
Astellas Pharma Inc. – Combination Treatment Modalities in Pipeline, H2 2011
Astellas Pharma Inc. – Filed, H2 2011
Astellas Pharma Inc. – Phase III, H2 2011
Astellas Pharma Inc. - Phase II, H2 2011
Astellas Pharma Inc. - Phase I, H2 2011
Astellas Pharma Inc. - Pipeline By Therapeutic Class, H2 2011
Astellas Pharma Inc. - Pipeline By Target, H2 2011
Astellas Pharma Inc. – Pipeline By Route of Administration, H2 2011
Astellas Pharma Inc. – Pipeline By Molecule Type, H2 2011
Astellas Pharma Inc. – Recent Pipeline Updates, H2 2011
Astellas Pharma Inc. - Dormant Developmental Projects, 2010
Astellas Pharma Inc. - Discontinued Pipeline Products, 2010
Astellas Pharma Inc., Other Locations
Astellas Pharma Inc., Subsidiaries
Astellas Pharma Inc., Deals Summary
MediGene Completes Sale Of European Rights For Eligard To Astellas
Astellas Pharma To Acquire Assets And Rights Of Diannexin From Pharmaceutical Product
Prosidion Acquires Pharmaceutical Assets From 7TM Pharma
Astellas Pharma Acquires AMEVIVE Rights And Assets From Biogen Idec
Astellas Pharma Acquires Research Facility From Dynogen Dynogen Pharmaceuticals
Prosidion Acquires Dipeptidyl Peptidase-IV Platform From Probiodrug
Prolysis Secures $10 Million In Venture Financing
Teijin Pharma Enters Into Distribution Agreement With Astellas Pharma For Febuxostat
Pfizer Amends Its Co-Promotion Agreement With Astellas Pharma
Astellas Pharma Enters Into Distribution Agreement With Abbott Japan For Luvox
BioFocus Enters Into Co-Development Agreement With Astellas Pharma
Multiple Myeloma Research Foundation Enters Into Co-Development Agreement With Astellas Pharma
Cell Signaling Technology Enters Into Co-Marketing Agreement With Astellas Pharma
Maruho Enters Into Co-Marketing Agreement With Astellas
Astellas Pharma Enters Into Drug Discovery Collaboration With NITE
Astellas Pharma Enters Into An Agreement With Sanofi-Aventis
Dong-A Pharmaceutical Enters Into Co-Promotion Agreement With Astellas Pharma Korea
Astellas Pharma Enters Into Co-Development Agreement With UMN Pharma
Astellas Pharma Enters Into Co-Marketing Agreement With Bayer Schering Pharma
OM PHARMA Enters Into Co-Marketing Agreement With Astellas Pharma
Ambit Biosciences Enters Into Co-Development Agreement With Astellas Pharma
Medivation Enters Into Co-Development Agreement With Astellas Pharma
Maxygen Forms Joint Venture With Astellas Pharma
Pfizer Enter Into Co-Promotion Agreement With Astellas Pharma
Astellas Pharma Enters Into Co-Promotion Agreement With AstraZeneca
Astellas Pharma Enters Into Co-Marketing Agreement With Zogenix
REGiMMUNE Enters Into Co-Development Agreement With Astellas Pharma
Astellas Pharma Enters Into Agreement With Maxygen
Astellas Pharma Enters Into Collaboration Agreement With CoMentis
Zeria Pharmaceutical Enters Into Agreement With Astellas Pharma
Effector Cell Institute Enters Into Co-Development Agreement With Astellas Pharma
Astellas Pharma Enters Into Co-Development Agreement With Kyoto University
Cardiome Pharma Amends Its Co-Development Agreement With Astellas US
AtheroGenics Extends Its Agreement With Astellas Pharma
Astellas Pharma Enters Into Co-Promotion Agreement With Sanofi-Aventis
Astellas Pharma Enters Into Collaboration Agreement With Chugai Pharmaceutical And National Institute of Technology and Evaluation
Portola Pharmaceuticals Enters Into Co-Development Agreement With Astellas Pharma
Metabolex Extends Research Agreement With Astellas Pharma
Quark Enters Into Collaboration Agreement With Fujisawa
Astellas Pharma Enters In An Agreement With Roche
Oncolys BioPharma Enters Into Licensing Agreement With Astellas Pharma
Astellas Pharma Extends Collaboration With MorphoSys
MorphoSys Enters Into Licensing Agreement With Astellas Pharma
Astellas Pharma Enters Into Licensing Agreement With Ilypsa
OSI Pharmaceuticals Enters Into License Agreement With British Pharmaceutical Company
Insmed Enters Into A Licensing Agreement With Fujisawa
MediGene Enters Into Licensing Agreement With Astellas Pharma
GVK Biosciences Extends Licensing Agreement With Astellas Pharma
Aestus Therapeutics Enters Into Licensing Agreement With Prosidion For PSN-357
Evec Enters Into Licensing Agreement With Astellas Pharma
Vical Receives Antitrust Approval For Licensing Agreement With Astellas Pharma For TransVax
Astellas Pharma Enters Into Licensing Agreement With Cardeus Pharmaceuticals
Astellas Pharma Enters Into Licensing Agreement With AVEO Pharmaceuticals For Tivozanib
Optimer Pharmaceuticals Enters Into Licensing Agreement With Astellas Pharma Europe For Fidaxomicin
Astellas Pharma Europe Expands Its Licensing Agreement With TOLMAR For Eligard
Astellas Pharma Extends Licensing Agreement With AstraZeneca
Astellas Pharma Enters Into Licensing Agreement With ASKA Pharmaceutical For AKP-002
Astellas Pharma Extends Licensing Agreement With Regeneron Pharmaceuticals
Teijin Pharma Enters Into An Agreement With Astellas Pharma
Basilea Pharmaceutica Enters Into Licensing, Co-Development And Co-Promotion Agreement with Astellas Pharma
Hikma Pharmaceuticals Enters Into Licensing Agreement With Astellas Pharma
Ironwood Pharmaceuticals Enters Into Licensing Agreement With Astellas Pharma
Teijin Pharma Enters Into Licensing Agreement With Astellas Pharma Taiwan
Millipore Enters Into Licensing Agreement With Astellas
MorphoSys Enters Into Licensing Agreement With Astellas
GlaxoSmithKline Pharmaceuticals Enters Into Licensing Agreement With Astellas Pharma
Astellas Pharma Enters Into Licensing Agreement With Regeneron Pharmaceuticals
Astellas Enters Into License Agreement With Kirin Brewery Company
Eli Lilly Enters Into Licensing Agreement With OSI Pharmaceuticals
Prosidion Enters Into License Agreement With Bristol-Myers Squibb
Ingenuity Systems Enters Into Licensing Agreement With Astellas Pharma
Theravance Extends Licensing Agreement With Astellas
CV Therapeutics Amends Licensing Agreement With Astellas US
Astellas Pharma Enters Into Licensing Agreement With FibroGen
Sanofi-Aventis Enters Into Licensing Agreement With Astellas Pharma
Astellas Pharma Enters Into Licensing Agreement With Toyama Chemical
Astellas Pharma Enters Into Licensing Agreement With Immuno-Bioogical Laboratories
Ferring Pharmaceuticals Enters Into Licensing Agreement With Astellas Pharma
Astellas Pharma Enters Into Licensing Agreement With XenoPort
Astellas Pharma Enters Into Licensing Agreement With Theravance
OSI Pharmaceuticals Enters Into License Agreement With Japanese Pharmaceutical Company
Fujisawa Pharmaceutical Enters Into Licensing Agreement With Carlsson Research
Cytori Therapeutics Announces Private Placement Of $10 Million
Cardiome Pharma Completes Private Placement Of $4 Million
Prosidion Completes Sale Of Dipeptidyl Peptidase IV Patent Estate And Associated Royalty Interest To Royalty Pharma
APP Pharmaceuticals Acquires Manufacturing Plant From Astellas Phama
Temmler Pharma Acquires Three European Plants From Astellas Pharma
QLT Acquires Full Rights To Aczone From Astellas
Astellas Pharma Acquires Remaining 83% Interest In Perseid Therapeutics From Maxygen
Astellas Pharma Acquires OSI Pharmaceuticals
Astellas Acquires Agensys
Astellas Pharma Sells Hoshienu Pharma To Choseido Pharmaceutical
Daiichi Sankyo Acquires Zepharma From Astellas Pharma
OSI Pharmaceuticals Acquires Remaining Stake In Prosidion
Prosidion Acquires AdipoGenix

LIST OF FIGURES

Astellas Pharma Inc. – Pipeline by Therapy Area and Indication, H2 2011
Astellas Pharma Inc. – Pipeline by Stage of Development, H2 2011
Astellas Pharma Inc. – Monotherapy Products in Pipeline, H2 2011
Astellas Pharma Inc. – Combination Treatment Modalities in Pipeline, H2 2011
Astellas Pharma Inc. – Pipeline By Therapeutic Class, H2 2011
Astellas Pharma Inc. - Pipeline By Target, H2 2011
Astellas Pharma Inc. – Pipeline By Route of Administration, H2 2011
Astellas Pharma Inc. – Pipeline By Molecule Type, H2 2011

Ask Your Question

Astellas Pharma Inc. – Product Pipeline Review – H2 2011
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: